Clinical trial register · Poland

Clinical Trials in Krakow, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC

2705

Studies in scope

all four open statuses

1389

Recruiting now

open to new participants

512

Lead sponsors

across recruiting studies

Top sites

Warsaw 1315 Krakow 882 Poznan 705 Gdansk 657 Lodz 619

Trials with a site in Krakow

Status

Study

Lead sponsor

Phase

Enrol

Sites in Poland

Start

Recruiting

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

NCT06317805Pulmonary Arterial Hypertension

AOP Orphan Pharmaceuticals AG

Phase 4

110

Krakow, Otwock

2023-12-06

Active, closed

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06029972Ulcerative Colitis

Gilead Sciences

Phase 2

176

Krakow, Lublin, Poznan, Rzeszów, Sopot, Warsaw, Wroclaw

2023-12-05

Active, closed

A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

NCT06514807Essential Thrombocythaemia

DrugBesremi

AOP Orphan Pharmaceuticals AG

Phase 3

117

Gdansk, Katowice, Krakow, Lodz

2023-12-04

Active, closed

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)

NCT06127043Ulcerative Colitis

DrugRosnilimab

AnaptysBio, Inc.

Phase 2

132

Bydgoszcz, Częstochowa, Elblag, Katowice, Krakow, Lodz, Lublin, Poznan

2023-12-04

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Bydgoszcz, Krakow, Lublin, Przemyśl, Warsaw

2023-12-04

Active, closed

Renal Colic and Urolithiasis in Poland

NCT06176469Renal Colic, Urolithiasis

Mikolaj Przydacz

Observational

10,000

Krakow

2023-12-01

Recruiting

LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes

NCT06527027Lymph Node Neoplasm, Lymph Node Metastasis

Copernicus Memorial Hospital

Not applicable

1,000

Krakow, Lodz, Warsaw

2023-12-01

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716NASH With Fibrosis, MASH With Fibrosis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

1,650

Poznan, Krakow, Wroclaw, Warsaw, Gdansk, Gdynia, Częstochowa, Katowice

2023-12-01

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Bydgoszcz, Katowice, Krakow, Lublin, Warsaw

2023-11-29

Recruiting

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

NCT05866419Spinal Muscular Atrophy, Spine Deformity, Scoliosis

Alcyone Therapeutics, Inc

Not applicable

Krakow, Lodz

2023-11-27

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Bialystok, Bydgoszcz, Gdansk, Gdynia, Konin, Krakow, Legnica, Lodz

2023-11-23

Active, closed

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Exemestane·Anastrozole·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

510

Lublin, Lodz, Otwock, Brzozów, Rzeszów, Gdynia, Gdansk, Krakow

2023-11-16

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsAvutometinib·Sotorasib·Pembrolizumab

Amgen

Phase 3

750

Bialystok, Bystra, Gdynia, Gliwice, Krakow, Lodz, Lublin, Poznan

2023-11-16

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

NCT06063967Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

289

Krakow, Warsaw

2023-11-15

Active, closed

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420Neoplasms, Head and Neck

DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab

GlaxoSmithKline

Phase 2

316

Bielsko-Biala, Katowice, Krakow, Przemyśl, Siedlce, Warsaw

2023-11-14

Active, closed

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

NCT06097364Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan

Regeneron Pharmaceuticals

Phase 3

733

Krakow, Skorzewo, Bydgoszcz, Gdansk, Katowice, Lodz, Lublin, Warsaw

2023-11-14

Active, closed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379Breast Cancer

DrugsDato-DXd·Epirubicin·Xeloda·Olaparib

AstraZeneca

Phase 3

1,902

Bialystok, Bydgoszcz, Gdynia, Krakow, Lodz, Warsaw

2023-11-14

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

Bydgoszcz, Krakow, Warsaw, Bialystok, Katowice, Szczecin, Lodz

2023-11-08

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

Bydgoszcz, Krakow, Lodz, Sosnowiec, Warsaw

2023-11-08

Active, closed

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835Chronic Kidney Disease With High Proteinuria

DrugDapagliflozin

AstraZeneca

Phase 3

1,835

Chrzanów, Krakow, Lodz, Poznan, Radom, Rzeszów, Szczecin, Warsaw

2023-11-07

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Biała Podlaska, Gliwice, Krakow, Lodz, Poznan, Wieliszew

2023-10-31

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

Poznan, Krakow, Wroclaw, Bydgoszcz, Warsaw

2023-10-27

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Poznan, Torun, Krakow, Nowy Targ, Wadowice, Wroclaw, Warsaw, Chorzów

2023-10-25

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Bydgoszcz, Krakow, Bialystok, Gdansk, Olsztyn, Będzin, Katowice, Lodz

2023-10-25

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

NCT06047444Chronic Migraine

DrugsDysport·Botulinum toxin type A

Ipsen

Phase 3

759

Bydgoszcz, Gdynia, Katowice, Krakow, Lublin, Oświęcim

2023-10-12

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

NCT06095102Plaque Psoriasis

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

311

Bialystok, Krakow, Lodz, Osielsko, Poznan, Warsaw, Wroclaw

2023-10-12

Active, closed

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

NCT06095115Plaque Psoriasis

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

684

Bialystok, Elblag, Krakow, Lodz, Osielsko, Poznan, Warsaw, Wroclaw

2023-10-12

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Osielsko, Torun, Krakow, Wroclaw, Warsaw, Bialystok, Katowice, Elblag

2023-10-11

Active, closed

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756Arteriosclerosis, Hypercholesterolaemia

DrugEnlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

14,550

Poznan, Bydgoszcz, Torun, Chrzanów, Krakow, Tarnów, Legnica, Lublin

2023-10-09

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Bialystok, Biała Podlaska, Bydgoszcz, Gdansk, Gdynia, Koszalin, Krakow, Lodz

2023-10-05

Active, closed

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

NCT06072131Peripheral T Cell Lymphoma

DrugsBelinostat·Pralatrexate·CHOP·Prednisone

Acrotech Biopharma Inc.

Phase 3

504

Wroclaw, Krakow, Warsaw, Lodz

2023-10-04

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

NCT05755386IC-MPGN

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

106

Poznan, Bialystok, Krakow, Olsztyn, Warsaw, Wroclaw

2023-10-02

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457Episodic Migraine

DrugsDysport·Botulinum toxin type A

Ipsen

Phase 3

751

Bydgoszcz, Gdynia, Katowice, Krakow, Lublin, Oświęcim

2023-09-29

Active, closed

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

NCT06007677Hereditary Angioedema

DrugNavenibart

Astria Therapeutics, Inc.

Phase 2

Krakow

2023-09-26

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671Locally Advanced Cervical Cancer

DrugVolrustomig

AstraZeneca

Phase 3

800

Bialystok, Gdansk, Gliwice, Krakow, Lodz, Poznan, Warsaw, Wroclaw

2023-09-22

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Brzozów, Gda?sk, Katowice, Kielce, Krakow, Wroc?aw

2023-09-18

Active, closed

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941Sjögren's Syndrome

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

774

Krakow, Warsaw, Bydgoszcz, Lublin, Poznan, Wroclaw

2023-09-11

Recruiting

The ReTAVI Prospective Observational Registry

NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction

Institut für Pharmakologie und Präventive Medizin

Observational

250

Bialystok, Gdansk, Katowice, Krakow, Warsaw, Wroclaw

2023-09-05

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

NCT06016842Primary Biliary Cholangitis (PBC)

DrugElafibranor

Ipsen

Phase 3

276

Elblag, Katowice, Krakow, Lodz, Lublin, Małogoskie, Rzeszów, Sosnowiec

2023-08-31

Active, closed

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267Asthma

DrugAlbuterol sulfate

Teva Branded Pharmaceutical Products R&D LLC

Phase 3

2,772

Bialystok, Bydgoszcz, Elblag, Gdansk, Krakow, Lodz, Lublin, Maków Podhalański

2023-08-30

Active, closed

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

NCT05995964Atopic Dermatitis

DrugTilrekimig

Pfizer

Phase 2

507

Poznan, Krakow, Wroclaw, Katowice, Ostrowiec Świętokrzyski

2023-08-22

Active, closed

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

NCT06021522Tourette Syndrome

Emalex Biosciences Inc.

Phase 3

150

Katowice, Gdansk, Poznan, Krakow

2023-08-16

Active, closed

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610Primary IgA Nephropathy

Hoffmann-La Roche

Phase 3

459

Wroclaw, Krakow, Lodz, Opole, Poznan, Warsaw

2023-08-08

Active, closed

Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)

NCT05797740Multiple Sclerosis

DrugsMavenclad·Cladribine

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Observational

366

Krakow, Poznan, Szczecin

2023-08-03

Recruiting

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

NCT05639933Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia

Hoth Therapeutics, Inc.

Phase 2

152

Krakow, Lublin

2023-07-19

Active, closed

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

NCT05852691Breast Cancer

DrugsTobemstomig·Nab-paclitaxel·Pembrolizumab

Hoffmann-La Roche

Phase 2

Kielce, Krakow

2023-07-18

Recruiting

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

NCT05797831Endometrial Cancer

DrugNavtemadlin

Kartos Therapeutics, Inc.

Phase 2/3

268

Bialystok, Gdansk, Gliwice, Krakow, Olsztyn, Poznan, Warsaw, Wroclaw

2023-07-17

Recruiting

The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction

NCT05508035Heart Failure With Moderately Reduced Ejection Fraction

DrugsRamipril·Sacubitril / Valsartan

John Paul II Hospital, Krakow

Phase 3

488

Krakow

2023-07-13

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT05851443Moderate to Severe Asthma

DrugsICS/LABA·Povorcitinib

Incyte Corporation

Phase 2

247

Bialystok, Gdansk, Krakow, Lubin, Ostrowiec Świętokrzyski, Warsaw

2023-07-11

Active, closed

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

NCT05696717Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy

Theravance Biopharma

Phase 3

102

Gdansk, Katowice, Krakow, Oświęcim

2023-06-27

Active, closed

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480SLE

DrugEnvudeucitinib

Alumis Inc

Phase 2

408

Bytom, Bialystok, Bydgoszcz, Częstochowa, Krakow, Nadarzyn, Poznan, Sosnowiec

2023-06-26

Active, closed

A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT05776472Paroxysmal Nocturnal Hemoglobinuria

DrugPegcetacoplan

Swedish Orphan Biovitrum

Observational

165

Bialystok, Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Warsaw

2023-06-26

Recruiting

Novel Setup Algorithm for Cardiac Neuromodulation Therapy

NCT05719454Hypertension, Bradycardia

BackBeat Medical Inc

Not applicable

Krakow, Poznan, Szczecin, Warsaw, Zabrze

2023-06-21

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082Non-Small Cell Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 1/2

320

Gda?sk, Krakow, Olsztyn

2023-06-20

Recruiting

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

NCT05877963Relapsing Multiple Sclerosis

DrugUblituximab

TG Therapeutics, Inc.

Phase 3

800

Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Olsztyn, Poznan, Warsaw

2023-06-13

Recruiting

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

NCT05897320Episodic Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

315

Krakow, Oświęcim, Lublin, Warsaw

2023-06-08

Active, closed

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases

Alexion Pharmaceuticals, Inc.

Phase 3

165

Krakow, Lodz, Warsaw

2023-06-07

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

Bydgoszcz, Gdynia, Gliwice, Konin, Koszalin, Krakow, Rzeszów, Warsaw

2023-06-07

By invitation

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

NCT05707949Migraine Prophylaxis

DrugAtogepant

AbbVie

Phase 3

650

Poznan, Bydgoszcz, Krakow, Lublin, Warsaw, Wroclaw

2023-06-05

Active, closed

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Small Cell Lung Cancer (SCLC)

DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan

Amgen

Phase 3

509

Bystra, Krakow, Poznan

2023-05-31

Active, closed

A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

NCT05735327Non-small Cell Lung Cancer (NSCLC)

Takeda

Observational

Wroclaw, Poznan, Bydgoszcz, Krakow, Lublin, Warsaw, Rzeszów, Bystra

2023-05-22

Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786Myositis

Pfizer

Phase 3

318

Poznan, Krakow, Warsaw, Bialystok

2023-05-20

Recruiting

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT05442567Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

240

Krakow, Wroclaw, Warsaw, Rzeszów, Gdansk, Katowice, Szczecin, Lodz

2023-05-16

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Gdansk, Krakow, Lodz, Lublin, Warsaw

2023-05-08

Recruiting

Endometriosis and Peritoneal Dysbiosis

NCT05824819Endometriosis, Infertility Unexplained

Jagiellonian University

Not applicable

100

Krakow

2023-05-01

Recruiting

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

NCT05711394Episodic Migraine

DrugAtogepant

AbbVie

Phase 3

450

Poznan, Bydgoszcz, Krakow, Lublin, Warsaw, Wroclaw

2023-05-01

Recruiting

Automated Fetal Cardiac Function in Babies Affected by Heart Diseases

NCT05698277Congenital Heart Defect, Cardiac Function

Anna Erenbourg

Observational

495

Krakow

2023-05-01

Active, closed

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

NCT05805501Renal Cell Carcinoma

DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda

Hoffmann-La Roche

Phase 2

199

Brzozów, Bydgoszcz, Krakow, Późna

2023-04-21

Active, closed

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

NCT05645692Urothelial Cancer

DrugsTobemstomig·Tiragolumab·Atezolizumab

Hoffmann-La Roche

Phase 2

204

Koszalin, Krakow, Późna, Warsaw

2023-04-13

Active, closed

TrEatment Approach in the Multimodal Era Registry

NCT05629052Chronic Thromboembolic Pulmonary Hypertension, CTEPH

International CTEPH Association

Observational

1,000

Krakow, Otwock

2023-04-12

Active, closed

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

NCT05692180Asthma

DrugBenralizumab

AstraZeneca

Phase 3

Bialystok, Krakow, Lodz, Skarżysko-Kamienna, Tarnów

2023-04-05

Active, closed

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906Biochemically Recurrent Prostate Cancer

DrugDarolutamide

Bayer

Phase 3

985

Bydgoszcz, Kielce, Krakow, Lublin, Warsaw, Wroclaw

2023-04-03

Recruiting

Psychological Factors and Pain in Orthopedic Surgery Patients

NCT06707363Orthopedic Surgical Procedures

Jagiellonian University

Observational

170

Krakow

2023-04-03

Active, closed

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

NCT05819359Parkinson's Disease

Bial R&D Investments, S.A.

Phase 2

237

Bydgoszcz, Krakow, Lodz

2023-03-31

Active, closed

A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

NCT05622708Non-radiographic Axial Spondyloarthritis

DrugSecukinumab

Novartis Pharmaceuticals

Phase 4

240

Krakow, Warsaw, Bydgoszcz, Sochaczew, Torun

2023-03-28

Recruiting

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

NCT05201404Hepatocellular Carcinoma, Cirrhosis

DrugNamodenoson

Can-Fite BioPharma

Phase 3

471

Koszalin, Krakow, Mysłowice, Przemyśl, Warsaw, Wroclaw

2023-03-15

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

Poznan, Krakow, Siedlce, Gdynia

2023-03-15

By invitation

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05735483Atopic Dermatitis, Eczema

DrugLebrikizumab

Eli Lilly and Company

Phase 3

338

Warsaw, Krakow, Gdansk, Lodz

2023-03-09

Active, closed

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

14,012

Krakow, Bialystok, Bydgoszcz, Bygdoszcz, Chorzów, Elblag, Gdynia, Grudziądz

2023-03-09

Active, closed

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399Melanoma

DrugsPhesgo·Relatlimab·Nivolumab

Bristol-Myers Squibb

Phase 3

579

Bydgoszcz, Krakow, Opole, Poznan, Warsaw

2023-03-06

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

Krakow, Warsaw, Gdansk, Lodz

2023-03-03

Active, closed

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

NCT05669755Cardiovascular Disease

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

7,101

Ruda Śląska, Dąbrówka, Bygdoszcz, Chrzanów, Krakow, Wroclaw, Lublin, Poniatowa

2023-03-01

Recruiting

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

NCT05723198Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases

DrugBaricitinib

Eli Lilly and Company

Phase 3

595

Gdansk, Katowice, Kielce, Krakow, Lodz, Rzeszów, Swietokrzyski, Warsaw

2023-02-27

By invitation

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects

NCT05594992Mucopolysaccharidosis II

DrugJR-141

JCR Pharmaceuticals Co., Ltd.

Phase 3

Krakow

2023-02-22

Recruiting

Lesser Poland Cracovian Heart Failure Registry

NCT05746923Heart Failure, Heart Failure Acute

Jagiellonian University

Observational

2,500

Krakow

2023-02-15

Active, closed

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

NCT05685238Haemophilia A, Haemophilia A With Inhibitors

Novo Nordisk A/S

Phase 3

451

Poznan, Wroclaw, Warsaw, Krakow, Lublin

2023-02-13

Active, closed

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT05686551Huntington Disease

Hoffmann-La Roche

Phase 2

301

Gdansk, Krakow, Warsaw

2023-02-03

Recruiting

The Impact of Physical Training Under Normobaric Hypoxia on Oxidative Stress Level, Inflammatory State, Intestinal Damage, and Mitochondrial Metabolism in Young Males

NCT06204731Hypoxia, Altitude

University School of Physical Education, Krakow, Poland

Not applicable

Krakow

2023-02-01

Active, closed

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

NCT05662319Hemophilia

DrugsAntithrombin·Clotting factor concentrates·Fitusiran

Sanofi

Phase 3

Krakow, Lodz, Warsaw

2023-02-01

Recruiting

Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD

NCT04433052Coronary Heart Disease

Tampere University

Not applicable

12,000

Bialystok, Katowice, Krakow, Lublin, Toruniak, Warsaw

2023-02-01

Active, closed

Dynamics of Psychotherapy and Treatment Outcomes

NCT07017543Mental Disorders, Neurotic Disorders, Personality Disorders

University Hospital in Krakow

Not applicable

Krakow

2023-02-01

Active, closed

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack

DrugDexpramipexole Dihydrochloride

Areteia Therapeutics

Phase 3

600

Będzin, Bialystok, Gdansk, Giżycko, Katowice, Krakow, Lodz, Lublin

2023-01-30

Active, closed

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

NCT05405361Multifocal Motor Neuropathy (MMN)

DrugEmpasiprubart

argenx

Phase 2

Krakow, Warsaw

2023-01-18

Active, closed

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

NCT05642780Solid Tumor

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Klus Pharma Inc.

Phase 2

240

Gdynia, Krakow, Warsaw

2023-01-17

Active, closed

ABTECT - Maintenance

NCT05535946Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 3

1,116

Bialystok, Bydgoszcz, Kalisz, Kielce, Knurów, Krakow, Lodz, Lublin

2023-01-16

Active, closed

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT05620407Systemic Lupus Erythematosus

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

513

Poznan, Krakow, Lublin, Warsaw, Chorzów, Elblag, Szczecin, Wroclaw

2023-01-12

Active, closed

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT05617677Systemic Lupus Erythematosus

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

516

Poznan, Bydgoszcz, Krakow, Nadarzyn, Warsaw, Katowice, Bialystok, Lublin

2023-01-12

Active, closed

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT05668013Crohn Disease, Colitis, Ulcerative

DrugDuvakitug

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

247

Bydgoszcz, Częstochowa, Elblag, Gdansk, Katowice, Krakow, Kłodzko, Lodz

2023-01-11

By invitation

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT05396105Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 2/3

150

Krakow

2022-12-28

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Atrial Fibrillation (AF)

DrugAbelacimab

Anthos Therapeutics, Inc.

Phase 3

2,500

Bialystok, Czeladź, Elblag, Gdynia, Katowice, Krakow, Legnica, Lodz

2022-12-27

Recruiting

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

NCT05645107Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma

DrugXembify

Grifols Therapeutics LLC

Phase 3

386

Torun, Krakow, Legnica, Wałbrzych, Słupsk, Bydgoszcz, Olsztyn

2022-12-26

Recruiting

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

NCT05287126Ulcerative Colitis

DrugEtrasimod

Pfizer

Phase 2

Warsaw, Katowice, Krakow, Szczecin, Wroclaw

2022-12-16

Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916Breast Cancer

Greenwich LifeSciences, Inc.

Phase 3

2,250

Gdansk, Konin, Krakow, Opole, Poznan, Rzeszów, Słupsk, Warsaw

2022-12-16

Active, closed

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500Lupus Erythematosus, Systemic

DrugCenerimod

Viatris Innovation GmbH

Phase 3

470

Bialystok, Częstochowa, Katowice, Krakow, Lublin, Wroclaw

2022-12-13

Active, closed

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

NCT05501886Breast Cancer

DrugsGedatolisib·Alpelisib·Palbociclib·Fulvestrant

Celcuity Inc

Phase 3

701

Bydgoszcz, Konin, Krakow, Lodz, Opole, Siedlce, Szczecin, Warsaw

2022-12-08

By invitation

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

DrugEplontersen

Ionis Pharmaceuticals, Inc.

Phase 3

1,400

Krakow

2022-11-30

Active, closed

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

NCT05588843Colitis Ulcerative

Sanofi

Phase 2

187

Włocławek, Wroclaw, Łęczna, Warsaw, Gdynia, Katowice, Tychy, Krakow

2022-11-25

Active, closed

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3

260

Bydgoszcz, Katowice, Krakow, Lublin, Poznan

2022-11-21

Active, closed

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

NCT05407324Amyotrophic Lateral Sclerosis

Corcept Therapeutics

Phase 2

279

Bydgoszcz, Krakow, Warsaw

2022-11-15

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

Bialystok, Gdansk, Krakow, Lodz, Warsaw, Wroclaw

2022-11-08

Recruiting

Analgesic Effect of Accelerated Repetitive Transcranial Magnetic Stimulation in Neuropathic Pain

NCT05295498Peripheral Neuropathy

Jakub Antczak

Not applicable

Krakow

2022-11-04

Active, closed

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT05567796Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

3,400

Bydgoszcz, Krakow, Legnica, Lublin, Warsaw, Bialystok, Gdansk, Katowice

2022-11-01

Active, closed

Berotralstat Treatment in Children With Hereditary Angioedema

NCT05453968Hereditary Angioedema, Pediatric

DrugBerotralstat

BioCryst Pharmaceuticals

Phase 3

Krakow

2022-10-25

Active, closed

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05559359Atopic Dermatitis, Eczema

DrugLebrikizumab

Eli Lilly and Company

Phase 3

377

Gdansk, Krakow, Lodz, Warsaw

2022-10-18

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Bialystok, Katowice, Krakow, Lodz, Skorzewo, Warsaw

2022-10-14

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Brzozów, Gdansk, Katowice, Kielce, Krakow, Lublin, Olsztyn, Szczecin

2022-10-13

Active, closed

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

NCT05556512Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

15,374

Bialystok, Bydgoszcz, Chorzów, Elblag, Gdansk, Krakow, Lodz, Lublin

2022-10-11

Active, closed

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases

DrugDonanemab

Eli Lilly and Company

Phase 3

1,500

Bialystok, Bydgoszcz, Gdansk, Katowice, Krakow, Poznan, Szczecin, Warsaw

2022-10-10

Active, closed

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease

DrugGuselkumab

Janssen-Cilag Ltd.

Phase 3

288

Bialystok, Krakow, Lodz, Rzeszów, Szczecin, Torun, Warsaw, Wroclaw

2022-09-27

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NCT05503264NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis

DrugSatralizumab

Hoffmann-La Roche

Phase 3

122

Krakow, Zabrze

2022-09-27

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

201

Chorzów, Krakow, Lublin, Poznan

2022-09-23

Recruiting

Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion

NCT05759078Myocardial Infarction, Acute

DrugsSodium Chloride Inj·Ferinject

Wroclaw Medical University

Phase 4

1,000

Bydgoszcz, Grudziądz, Torun, Chrzanów, Gorlice, Krakow, Nowy Targ, Oświęcim

2022-09-22

Recruiting

INSIGHTFUL-FFR Clinical Trial

NCT05437900Coronary Artery Disease, Acute Coronary Syndrome

CoreAalst BV

Phase 4

2,500

Bydgoszcz, Krakow, Warsaw

2022-09-22

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib

Celgene

Phase 3

810

Skórzewo, Torun, Krakow, Warsaw, Słupsk, Katowice

2022-09-20

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Piła, Skórzewo, Krakow, Gdynia, Kielce

2022-09-20

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Bydgoszcz, Krakow, Lodz, Lublin, Nowy Targ, Olsztyn, Poznan, Rzeszów

2022-09-19

Active, closed

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

NCT05540327Systemic Lupus Erythematosus

DrugEnpatoran

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2

381

Bialystok, Kościan, Krakow, Poznan, Szczecin, Warsaw

2022-09-16

Active, closed

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsCeralasertib·Durvalumab·Docetaxel

AstraZeneca

Phase 3

594

Gdansk, Krakow, Poznan, Skórzewo

2022-09-15

Active, closed

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05528510Colitis, Ulcerative

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

418

Bialystok, Bydgoszcz, Chojnice, Krakow, Lublin, Poznan, Rzeszów, Szczecin

2022-09-13

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

Kielce, Krakow, Krosno, Lodz, Rzeszów, Warsaw, Wroclaw

2022-09-13

Active, closed

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05057494Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DrugsAcalabrutinib·Obinutuzumab·Venetoclax

AstraZeneca

Phase 3

607

Bydgoszcz, Gdansk, Katowice, Krakow, Lódz, Lublin

2022-09-12

Recruiting

Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

NCT06506084Polycythemia Vera

DrugBesremi

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

429

Gdansk, Katowice, Krakow, Lodz, Wroclaw

2022-09-08

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Gliwice, Krakow, Lodz, Poznan, Warsaw

2022-09-06

Active, closed

Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma

DrugSonrotoclax

BeOne Medicines

Phase 1/2

125

Gdansk, Krakow, Lublin

2022-09-05

Recruiting

Asciminib Roll-over Study

NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 4

347

Katowice, Krakow, Warsaw, Wroclaw

2022-08-30

Active, closed

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

Biogen

Phase 2

416

Bialystok, Bydgoszcz, Katowice, Krakow, Lodz, Lublin, Sopot, Warsaw

2022-08-24

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Torun, Krakow, Tarnów, Wroclaw, Lublin, Lodz, Warsaw, Rzeszów

2022-08-22

Active, closed

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134Melanoma

DrugsCeralasertib·Durvalumab

AstraZeneca

Phase 2

194

Brzozów, Gdansk, Krakow, Lodz, Poznan, Warsaw

2022-08-11

Active, closed

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 3

418

Bydgoszcz, Krakow, Otwock, Poznan, Warsaw

2022-08-05

Active, closed

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214Sjogren Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

506

Poznan, Krakow, Wroclaw, Warsaw

2022-08-04

Active, closed

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

NCT05297448Hepatic Encephalopathy

DrugRifaximin SSD

Bausch Health Americas, Inc.

Phase 3

466

Bydgoszcz, Katowice, Krakow, Mysłowice, Staszów, Wroclaw

2022-08-03

Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

DrugsPirtobrutinib·Ibrutinib

Loxo Oncology, Inc.

Phase 3

737

Biała Podlaska, Bydgoszcz, Gdansk, Katowice, Krakow, Lublin, Skórzewo, Wroclaw

2022-07-22

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471Crohn's Disease

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

703

Bydgoszcz, Krakow, Lodz, Lublin, Olsztyn, Poznan, Rzeszów, Sopot

2022-07-22

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

DrugsZilovertamab vedotin·Nemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

189

Krakow, Lublin, Warsaw, Olsztyn, Lodz, Kielce

2022-07-21

Active, closed

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

NCT05222555Diffuse Large B Cell Lymphoma

DrugsTafasitamab·Lenalidomide

Incyte Corporation

Phase 1/2

Skórzewo, Krakow, Wroclaw, Warsaw, Opole, Gdynia, Lodz, Olsztyn

2022-07-19

Active, closed

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114Hereditary Angioedema

DrugDonidalorsen

Ionis Pharmaceuticals, Inc.

Phase 3

154

Krakow

2022-07-13

Active, closed

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

NCT04991116Psoriatic Arthritis

Sun Pharmaceutical Industries Limited

Phase 3

529

Bialystok, Krakow, Lublin, Nadarzyn, Olsztyn, Poznan, Torun, Warsaw

2022-06-30

Active, closed

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997Multiple Myeloma

DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone

Celgene

Phase 3

939

Bialystok, Krakow, Nowy Sącz, Poznan, Warsaw, Wałbrzych

2022-06-23

Active, closed

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

NCT05405166Plasma Cell Myeloma Recurrent

DrugsParacetamol / Acetaminophen·Montelukast·Diphenhydramine·Isatuximab

Sanofi

Phase 3

531

Krakow, Wroclaw, Lublin

2022-06-23

Recruiting

CytOSorb TreatMent Of Critically Ill PatientS Registry

NCT05146336Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis

CytoSorbents, Inc

Observational

3,000

Krakow, Wroclaw

2022-06-22

Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632Adult Acute Myeloid Leukemia

Priothera SAS

Phase 3

366

Krakow, Katowice, Gdansk, Warsaw

2022-06-16

Active, closed

Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)

NCT05279651Myocardial Injury After Noncardiac Surgery (MINS), Myocardial Ischemia

DrugIvabradine

Jagiellonian University

Phase 3

2,146

Bydgoszcz, Ciechanów, Cieszyn, Gdansk, Gmina Końskie, Katowice, Krakow, Lodz

2022-06-13

By invitation

A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

NCT05352919Systemic Lupus Erythematosus (SLE)

DrugLitifilimab

Biogen

Phase 3

864

Bialystok, Bydgoszcz, Bytom, Krakow, Malbork, Poznan, Warsaw

2022-06-10

Active, closed

THIO Sequenced With Cemiplimab in Advanced NSCLC

NCT05208944Carcinoma, Non-Small-Cell Lung

DrugsThiotepa·Cemiplimab

Maia Biotechnology

Phase 2

227

Oświęcim, Bydgoszcz, Krakow, Lodz, Lublin, Poznan, Rzeszów, Skorzewo

2022-06-08

Recruiting

Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning in Myasthenia Gravis

NCT05337891Myasthenia Gravis

Jagiellonian University

Observational

Krakow

2022-06-03

Recruiting

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT05076175Colitis, Ulcerative

DrugOzanimod

Bristol-Myers Squibb

Phase 2/3

120

Krakow, Wroclaw, Warsaw, Rzeszów, Gdansk, Szczecin, Lodz

2022-05-30

Recruiting

Safety and Performance Study of the Optimum Transcatheter Aortic Valve

NCT04076150Severe Aortic Stenosis

Thubrikar Aortic Valve, Inc.

Not applicable

Krakow

2022-05-18

Recruiting

Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence

NCT04976153Fecal Incontinence

Innovacell GmbH

Phase 3

290

Krakow

2022-05-11

Active, closed

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

NCT05280548Fabry Disease

DrugsAgalsidase beta·Replagal·Venglustat·Migalastat HCl

Sanofi

Phase 3

104

Lodz, Krakow

2022-05-03

Active, closed

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

1,300

Bydgoszcz, Gda?sk, Katowice, Krakow, Lodz, Lublin, Olsztyn, Plewiska

2022-05-03

Active, closed

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044Melanoma

Pierre Fabre Medicament

Phase 3

815

Gliwice, Konin, Krakow, Poznan, Skórzewo, Warsaw, Wroclaw

2022-05-02

Recruiting

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

NCT05219617Seizures, Lennox Gastaut Syndrome

SK Life Science, Inc.

Phase 3

252

Poznan, Krakow

2022-04-28

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)

DrugBexobrutideg

Nurix Therapeutics, Inc.

Phase 1

572

Skórzewo, Krakow, Wroclaw, Warsaw, Katowice, Lublin

2022-04-13

Active, closed

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

NCT05210790Polycythemia Vera

DrugRusfertide

Protagonist Therapeutics, Inc.

Phase 3

293

Brzozów, Bydgoszcz, Gdansk, Krakow, Lodz, Torun, Warsaw, Wroclaw

2022-04-11

By invitation

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

NCT05248659Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2/3

600

Krakow, Lodz

2022-04-05

Active, closed

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

NCT05303636Change in Bone Mineral Density, Bone Loss

DrugDrospirenone

Insud Pharma

Phase 4

1,536

Bialystok, Katowice, Krakow, Lodz, Warsaw

2022-03-28

Recruiting

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

NCT04804553Active Juvenile Psoriatic Arthritis

DrugApremilast

Amgen

Phase 3

Krakow, Lodz, Warsaw

2022-03-17

Active, closed

COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events

NCT05333068Multivessel Coronary Artery Disease, Ischemia, Vulnerable Plaque, Coronary Artery Disease

Diagram B.V.

Not applicable

1,223

Katowice, Krakow, Lubin, Warsaw, Wroclaw

2022-03-16

Active, closed

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

530

Bialystok, Krakow, Lodz

2022-03-15

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Bydgoszcz, Gdansk, Katowice, Krakow, Poznan, Torun, Warsaw

2022-03-10

Recruiting

A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma

NCT05100056Hodgkin Lymphoma

Takeda

Observational

Wroclaw, Poznan, Krakow, Lublin, Tomaszow Mazowiecki, Warsaw, Gdansk, Katowice

2022-03-08

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DrugsMosunetuzumab·Venclexta·Tocilizumab·Venetoclax

Hoffmann-La Roche

Phase 1

332

Gda?sk, Krakow, Wroc?aw

2022-03-07

Active, closed

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder

UroGen Pharma Ltd.

Phase 3

240

Gliwice, Krakow, Poznan, Wieliszew

2022-03-01

Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

NCT05156398Migraine

DrugRimegepant

Pfizer

Phase 3

640

Poznan, Krakow, Wroclaw, Lublin, Warsaw, Katowice

2022-02-28

Recruiting

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05128825High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

DrugAzenosertib

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 2

310

Krakow, Bialystok, Gdynia

2022-02-17

Recruiting

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

NCT05263206Pruritus

DrugsFexofenadine·Dupilumab

Sanofi

Phase 3

284

Krakow, Wroclaw, Warsaw

2022-02-15

Active, closed

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

NCT04573023Mucopolysaccharidosis II

DrugsIdursulfase·JR-141

JCR Pharmaceuticals Co., Ltd.

Phase 3

Krakow

2022-02-14

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT04779320Crohn's Disease (CD)

DrugVedolizumab

Takeda

Phase 3

120

Krakow, Wroclaw, Warsaw, Rzeszów, Gdansk, Katowice, Szczecin, Lodz

2022-02-10

Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

NCT04879043Multiple Myeloma, Plasma Cell Disorder

DrugHDP-101

Heidelberg Pharma AG

Phase 1/2

Katowice, Krakow, Lodz, Opole, Skórzewo, Torun

2022-02-07

Active, closed

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

NCT05202509Atherosclerotic Cardiovascular Disease

DrugObicetrapib

NewAmsterdam Pharma

Phase 3

9,541

Bydgoszcz, Chorzów, Elblag, Gdansk, Gdynia, Grodzisk Mazowiecki, Katowice, Krakow

2022-02-07

By invitation

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

300

Bydgoszcz, Gdansk, Krakow, Lublin, Nowa Sól, Świdnik

2022-02-03

Recruiting

Acute Stroke of CArotid Artery Bifurcation Origin Treated With Use oF the MicronEt-covered CGUARD (SAFEGUARD-STROKE)

NCT05195658Carotid Artery Stenosis, Acute Ischemic Stroke

John Paul II Hospital, Krakow

Observational

Krakow

2022-01-30

Active, closed

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT05197049Crohn Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

350

Bialystok, Bydgoszcz, Chojnice, Chrzanów, Knurów, Krakow, Lodz, Lublin

2022-01-19

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma

DrugsZilovertamab vedotin·Granulocyte Colony-Stimulating Factor·Riabni·G-Csf

Merck Sharp & Dohme LLC

Phase 2/3

290

Krakow, Wałbrzych, Wroclaw, Lublin, Warsaw, Gdynia, Słupsk, Katowice

2022-01-14

Active, closed

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

NCT05217628Trigeminal Neuralgia

Noema Pharma AG

Phase 2/3

166

Dąbrowa Górnicza, Krakow, Lodz, Lublin, Wroclaw

2022-01-11

Active, closed

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT05081609Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer

DrugsTrastuzumab emtansine·Trastuzumab·Pembrolizumab

Ascendis Pharma Oncology Division A/S

Phase 1/2

320

Krakow, Poznan, Warsaw

2022-01-11

Active, closed

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100Carcinoma, Non-Small-Cell Lung

DrugSelpercatinib

Eli Lilly and Company

Phase 3

152

Krakow

2021-12-20

Active, closed

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

NCT05164341Partial Lipodystrophy

DrugMetreleptin

Chiesi Farmaceutici S.p.A.

Phase 3

Katowice, Krakow

2021-12-17

Active, closed

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

NCT05070858Generalized Myasthenia Gravis

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

288

Poznan, Krakow, Warsaw, Gdansk

2021-12-14

Active, closed

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

NCT04954859Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

360

Gdansk, Krakow, Lublin, Mysłowice, Żychlin, Łańcut

2021-12-14

Recruiting

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

350

Bydgoszcz, Gdansk, Krakow, Lublin, Nowa Sól, Poznan, Świdnik

2021-12-07

Active, closed

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

NCT05177835Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 2

203

Krakow, Lublin, Oświęcim, Piotrkow Trybunalski, Poznan, Tarnów, Warsaw, Wroclaw

2021-12-03

Recruiting

Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease

NCT05272371High-Risk Neuroblastoma

Jagiellonian University

Phase 1

Krakow

2021-12-01

Recruiting

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

NCT05164172Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

600

Krakow, Oświęcim, Lublin, Warsaw

2021-12-01

Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT04910685Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis

Blueprint Medicines Corporation

Phase 2/3

534

Gdansk, Krakow

2021-11-30

Active, closed

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

NCT05091567Small-Cell Lung Cancer

DrugsLurbinectedin·Tecentriq·Etoposide·Atezolizumab

Hoffmann-La Roche

Phase 3

660

Gda?sk, Krakow, Olsztyn, Otwock, Poznan, Warsaw

2021-11-18

Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

NCT05065216Acute Stroke, Ischemic Stroke, Stroke

DiaMedica Therapeutics Inc

Phase 2/3

728

Katowice, Krakow, Warsaw, Wroclaw, Zielona Góra

2021-11-07

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSutent·Savolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

Gdansk, Gdynia, Krakow, Otwock, Poznan

2021-10-28

Recruiting

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223Metastatic Colorectal Cancer

DrugsDivarasib·Tiragolumab·Inavolisib·Tecentriq

Hoffmann-La Roche

Phase 1

542

Gdansk, Krakow, Poznan, Warsaw

2021-10-22

Active, closed

A Long-term Extension Study of Ustekinumab in Pediatric Participants

NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic

DrugUstekinumab

Janssen Research & Development, LLC

Phase 3

159

Krakow, Rzeszów, Sosnowiec, Torun, Warsaw

2021-10-18

Recruiting

Impacted Canine and Mixed-reality Technology - RCT

NCT06574477Tooth, Impacted

Piotr Fudalej

Not applicable

Krakow

2021-10-01

Recruiting

ContraBand™: Safety & Feasibility Study (RM-20-01)

NCT05230745Heart Failure, Left Sided

Restore Medical Ltd

Not applicable

Krakow, Lublin

2021-09-28

Active, closed

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

282

Iwaszkiewicza 5, Lublin, Gdansk, Skorzewo, Biała Podlaska, Bydgoszcz, Katowice, Krakow

2021-09-23

Active, closed

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

600

Gdynia, Katowice, Krakow, Lodz, Lublin, Torun, Warsaw

2021-09-20

Active, closed

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

NCT04884035Lymphoma, B-Cell

DrugsGolcadomide·Iberdomide·Polatuzumab Vedotin·Prednisolone

Celgene

Phase 1

224

Skórzewo, Gdansk, Krakow, Słomniki, Warsaw, Wroclaw

2021-09-15

Recruiting

TRAnscranial Doppler CErebral Blood Flow and Cognitive IMPAIRment in Heart Failure

NCT05250349Heart Failure, Cognitive Impairment, Carotid Stenosis

John Paul II Hospital, Krakow

Observational

300

Krakow

2021-09-01

Active, closed

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210Arthritis, Psoriatic

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 4

411

Bialystok, Bydgoszcz, Bytom, Elblag, Krakow, Lodz, Lublin, Nadarzyn

2021-08-30

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

NCT04961996Early Breast Cancer

DrugGiredestrant

Hoffmann-La Roche

Phase 3

4,170

Bydgoszcz, Gdynia, Gliwice, Grudziądz, Krakow, Lodz, Lublin, Poznan

2021-08-27

By invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719Acute Myocardial Infarction

Viatris Innovation GmbH

Phase 3

25,000

Bialystok, Bielsk Podlaski, Bielsko-Biala, Bydgoszcz, Gdansk, Katowice, Krakow, Krosno

2021-08-14

Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis

DrugSparsentan

Travere Therapeutics, Inc.

Phase 2

Krakow, Lodz, Warsaw

2021-08-12

Active, closed

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

NCT04640142Primary Immune Deficiency

Octapharma

Phase 3

Krakow

2021-08-04

Active, closed

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

NCT04790370Pulmonary Embolism

DrugsLMWH·Heparin

Boston Scientific Corporation

Phase 4

544

Krakow, Poznan, Warsaw

2021-08-02

Recruiting

Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence

NCT04597294Gastric Cancer

Jagiellonian University

Phase 3

600

Krakow

2021-08-01

By invitation

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

NCT04976322Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

760

Bialystok, Bydgoszcz, Katowice, Krakow, Lublin, Poznan, Warsaw, Wroclaw

2021-07-27

By invitation

Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies

NCT04933721Hereditary Angioedema, HAE

DrugBerotralstat

BioCryst Pharmaceuticals

Phase 3

139

Krakow

2021-07-23

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

NCT04951622Myasthenia Gravis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

199

Bydgoszcz, Katowice, Krakow, Lublin, Warsaw

2021-07-15

Recruiting

Valved Graft PMCF Study

NCT04754217Aortic Valve Disease, Ascending Aorta Abnormality, Aortic Dissection

Abbott Medical Devices

Observational

260

Kielce, Krakow, Lodz, Warsaw

2021-07-13

Active, closed

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

NCT04908202Psoriatic Arthritis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

670

Dąbrówka, Krakow, Nowy Targ, Wroclaw, Lublin, Świdnik, Nadarzyn, Warsaw

2021-07-13

Active, closed

Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting

NCT04900844Carotid Artery Stenosis

InspireMD

Not applicable

317

Katowice, Krakow

2021-07-01

Recruiting

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

NCT04965675Chronic Migraine in Children

DrugEptinezumab

H. Lundbeck A/S

Phase 3

285

Krakow, Oświęcim, Lublin, Warsaw

2021-06-30

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Katowice, Krakow, Olsztyn, Poznan, Rzeszów, Siedlce, Szczecin, Warsaw

2021-06-28

Recruiting

Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System

NCT04798261Pulmonary Embolism

Penumbra Inc.

Observational

1,500

Krakow, Otwock, Poznan, Warsaw

2021-06-25

Active, closed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761Breast Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 3

506

Gdansk, Krakow, Opole, Warsaw

2021-06-22

Active, closed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol

Merck Sharp & Dohme LLC

Phase 3

342

Bydgoszcz, Krakow, Siedlce, Warsaw, Wieliszew, Przemyśl, Bialystok, Gliwice

2021-06-18

Active, closed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098Arthritis, Psoriatic

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

1,054

Bialystok, Bydgoszcz, Elblag, Gdynia, Krakow, Lublin, Nadarzyn, Nowa Sól

2021-06-17

Active, closed

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

NCT04768972Amyotrophic Lateral Sclerosis

Ionis Pharmaceuticals, Inc.

Phase 3

Krakow

2021-06-14

Active, closed

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

1,140

Gliwice, Krakow, Warsaw

2021-06-09

Active, closed

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

NCT04877691Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

367

Katowice, Kościan, Krakow, Lodz, Lublin, Nowa Sól, Ustroń, Warsaw

2021-06-08

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04895241Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

548

Bialystok, Bydgoszcz, Bytom, Krakow, Lublin, Malbork, Nowa Sól, Poznan

2021-05-25

Active, closed

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

NCT04810078Clear Cell Renal Cell Carcinoma

DrugsBMS-986298·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

681

Biała Podlaska, Bydgoszcz, Gdansk, Krakow, Poznan, Warsaw

2021-05-21

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 3

815

Krakow, Otwock

2021-05-12

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Ribociclib·Abemaciclib·Palbociclib

AstraZeneca

Phase 3

893

Bydgoszcz, Krakow, Warsaw

2021-05-10

Active, closed

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

NCT04777331Parkinsons Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 2

586

?ód?, Bydgoszcz, Gda?sk, Krakow, Lublin, Rzeszów, Warsaw

2021-05-05

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362Breast Cancer

DrugsTrastuzumab emtansine·Herceptin·Tecentriq·Trastuzumab

Hoffmann-La Roche

Phase 3

1,188

Bialystok, Gda?sk, Gliwice, Krakow, Poznan, Warsaw

2021-05-04

Active, closed

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

NCT04660344Muscle-invasive Bladder Cancer

DrugsTecentriq·Atezolizumab

Hoffmann-La Roche

Phase 3

761

Krakow, Poznan, Warsaw, Wroclaw

2021-05-03

Recruiting

Simultaneous Cardiac Surgery and Micronet-covered Stent Carotid Revascularization in High Perioperative Stroke Risk Patients

NCT04973579Carotid Stenosis, Coronary Artery Disease, Valvular Heart Disease, Myocardial Infarction

John Paul II Hospital, Krakow

Observational

Krakow

2021-05-01

Recruiting

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774Spasticity

DrugsDysport·Corabotase

Ipsen

Phase 1/2

240

Gdansk, Katowice, Krakow, Lodz, Oświęcim, Poznan, Sandomierz, Warsaw

2021-04-29

Recruiting

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

NCT04743141Acute Treatment of Migraine

DrugRimegepant

Pfizer

Phase 3

600

Katowice, Krakow, Poznan, Wroclaw

2021-04-28

Active, closed

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma

DrugsTafasitamab·Lenalidomide·Rituximab

Incyte Corporation

Phase 3

654

Brzozów, Katowice, Krakow, Lodz, Lublin, Tomaszów Mazowiecki, Warsaw, Wroclaw

2021-04-15

Active, closed

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255Lymphoma, Mantle-Cell

DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib

Loxo Oncology, Inc.

Phase 3

500

Lublin, Gdansk, Krakow, Lodz, Skorzewo, Wroclaw

2021-04-08

Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia

DrugNemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

490

Krakow, Wroclaw, Warsaw, Opole, Gdynia

2021-04-05

Active, closed

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586023Relapsing Multiple Sclerosis

DrugsFenebrutinib·Teriflunomide

Hoffmann-La Roche

Phase 3

751

Bydgoszcz, Gdansk, Kielce, Krakow, Lodz, Oświęcim, Plewiska, Poznan

2021-03-24

Recruiting

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT04772079Plaque Psoriasis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

153

Krakow, Lodz, Warsaw, Wroclaw

2021-03-23

Active, closed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)

DrugFluzoparib

Jiangsu HengRui Medicine Co., Ltd.

Phase 3

496

Gdynia, Grudziądz, Kobylniki, Koszalin, Krakow, Poznan, Warsaw, Wroclaw

2021-03-18

Recruiting

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

NCT04715646Epilepsy

DrugBrivaracetam

UCB Biopharma SRL

Phase 3

Kielce, Krakow, Poznan

2021-03-11

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1

304

Gdansk, Krakow, Olsztyn, Tomaszów Mazowiecki, Warsaw

2021-03-09

Active, closed

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsIdelalisib·Truxima·Pirtobrutinib·Bendamustine

Loxo Oncology, Inc.

Phase 3

238

Iwaszkiewicza 5, Lublin, Gdansk, Gdynia, Brzozów, Bydgoszcz, Katowice, Krakow

2021-03-09

Active, closed

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

NCT04586231Carcinoma, Renal Cell

DrugsBelzutifan·Cabozantinib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

747

Poznan, Bydgoszcz, Krakow, Warsaw

2021-02-25

Active, closed

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis

DrugLuspatercept

Celgene

Phase 3

313

Gdansk, Krakow, Lodz, Poznan, Wałbrzych, Wroclaw

2021-02-25

Recruiting

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

DrugsNavtemadlin·Acalabrutinib

Kartos Therapeutics, Inc.

Phase 1/2

Gdansk, Gliwice, Krakow, Wroclaw

2021-02-23

Active, closed

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

NCT04755283Atrial Fibrillation (AF), Stroke

DrugsAbelacimab·Rivaroxaban

Anthos Therapeutics, Inc.

Phase 2

1,287

Gdynia, Chrzanów, Krakow, Wroclaw, Żarów, Lublin, Zamość, Płock

2021-02-02

Recruiting

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242Pediatric Migraine

Pfizer

Phase 3

2,100

Wroclaw, Katowice, Krakow, Poznan, Szczecin

2021-01-15

Active, closed

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

NCT04657991Melanoma

DrugsEncorafenib·Binimetinib·Keytruda·Pembrolizumab

Pfizer

Phase 3

257

Krakow, Poznan, Warsaw

2021-01-15

Active, closed

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

NCT04628494Diffuse Large B-cell Lymphoma

DrugEpcoritamab

Genmab

Phase 3

483

Gdansk, Katowice, Krakow, Lodz, Skorzewo, Wroclaw

2021-01-13

Active, closed

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04204616Prurigo Nodularis

DrugNemolizumab

Galderma R&D

Phase 3

500

Bydgoszcz, Chorzów, Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz

2021-01-11

Recruiting

iCorMicA - Stratified Medicine in Angina

NCT04674449Microvascular Angina, Angina, Stable, Ischemia With No Obstructive Coronary Arteries (INOCA), Coronary Microvascular Dysfunction (CMD)

NHS Greater Glasgow and Clyde

Not applicable

1,500

Krakow

2020-12-30

Recruiting

Secukinumab Open Label Roll-over Extension Protocol

NCT04638647Autoimmunity, Inflammation

DrugSecukinumab

Novartis Pharmaceuticals

Phase 4

1,000

Krakow, Wroclaw, Warsaw, Bialystok, Bydgoszcz, Poznan, Sochaczew, Torun

2020-12-22

Active, closed

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

NCT04490915Congenital Adrenal Hyperplasia

DrugCrinecerfont

Neurocrine Biosciences

Phase 3

182

Krakow, Poznan, Warsaw

2020-12-16

Recruiting

FS222 First in Human Study in Patients With Advanced Malignancies

NCT04740424Advanced Cancer, Metastatic Cancer

invoX Pharma Limited

Phase 1

260

Poznan, Krakow

2020-12-14

Active, closed

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

NCT04548999Multiple Sclerosis

DrugsOcrelizumab·Methylprednisolone

Hoffmann-La Roche

Phase 3

769

Bydgoszcz, Gdansk, Katowice, Krakow, Lodz, Lublin, Oświęcim, Plewiska

2020-12-03

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

DrugsAdagrasib·Pembrolizumab

Mirati Therapeutics Inc.

Phase 2/3

626

Gdansk, Kielce, Krakow, Lublin, Olsztyn, Otwock, Poznan, Skorzewo

2020-12-02

Active, closed

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia

DrugsEpcoritamab·Pirtobrutinib·Lenalidomide·Venetoclax

Genmab

Phase 1/2

194

Katowice, Krakow, Skorzewo

2020-11-25

Active, closed

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction

DrugDurvalumab

AstraZeneca

Phase 3

957

Bialystok, Gdansk, Krakow, Lodz, Poznan, Warsaw

2020-11-17

Active, closed

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

NCT04597125Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Bayer

Phase 4

654

Krakow, Wroclaw, Lublin, Warsaw, Koszalin

2020-11-09

Recruiting

LANDMARK Trial: a Randomised Controlled Trial of Myval THV

NCT04275726Aortic Valve Stenosis

Meril Life Sciences Pvt. Ltd.

Not applicable

988

Krakow, Gdansk, Katowice, Warsaw, Wroclaw

2020-11-04

Active, closed

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin

AstraZeneca

Phase 3

640

Katowice, Krakow, Lodz, Siedlce, Warsaw

2020-10-19

Active, closed

Myasthenia Gravis Inebilizumab Trial

NCT04524273Myasthenia Gravis

DrugInebilizumab

Amgen

Phase 3

238

Katowice, Krakow, Poznan, Warsaw

2020-10-15

Active, closed

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone

Acerta Pharma BV

Phase 3

611

Gdansk, Krakow, Lodz, Lublin, Warsaw, Wroclaw

2020-10-08

Active, closed

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623Multiple Myeloma

DrugsBelantamab mafodotin·Pomalidomide·Bortezomib·Dexamethasone

GlaxoSmithKline

Phase 3

302

Bydgoszcz, Gdansk, Krakow, Lodz, Wroclaw

2020-10-01

Active, closed

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611Crohn's Disease (CD)

DrugsSkyrizi·Risankizumab·Ustekinumab

AbbVie

Phase 3

527

Torun, Krakow, Warsaw

2020-09-30

Active, closed

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

NCT04497844Prostatic Neoplasms

DrugsAbiraterone acetate·Prednisone

Janssen Research & Development, LLC

Phase 3

696

Bydgoszcz, Gdynia, Konin, Krakow, Lodz, Lublin, Siedlce, Warsaw

2020-09-23

Active, closed

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

NCT04280718Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

DrugEfgartigimod PH20

argenx

Phase 2

229

Krakow, Lodz, Lublin, Warsaw

2020-09-18

Active, closed

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04384484Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

DrugsLoncastuximab Tesirine·Rituximab·Oxaliplatin·Gemcitabine

ADC Therapeutics S.A.

Phase 3

440

Krakow, Wroclaw, Gdynia, Katowice, Lodz, Opole, Skorzewo, Warsaw

2020-09-16

Recruiting

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

NCT04462770Dravet Syndrome

DrugClemizole HCl

Epygenix

Phase 3

150

Gdansk, Krakow, Warsaw

2020-09-15

Active, closed

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022Relapsed/Refractory Diffuse Large B-cell Lymphoma

DrugsSelinexor·Rituximab·Dexamethasone·Gemcitabine

Karyopharm Therapeutics Inc

Phase 2/3

501

Krakow, Gdynia, Wroclaw, Katowice, Skorzewo, Warsaw

2020-09-03

Active, closed

Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

NCT04565054Breast Cancer Female

DrugAbemaciclib

Women's Cancer Study Group GmbH

Phase 3

1,260

Gdansk, Krakow, Warsaw

2020-09-02

Active, closed

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

NCT04468984Myelofibrosis (MF)

DrugsNavitoclax·Ruxolitinib

AbbVie

Phase 3

330

Piła, Poznan, Krakow, Lublin, Warsaw, Gdansk, Katowice, Lodz

2020-08-31

Active, closed

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283Diffuse Large B-cell Lymphoma

DrugsBrentuximab Vedotin·Lenalidomide·Rituximab

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

240

Krakow, Torun

2020-08-20

Active, closed

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 2

477

Bydgoszcz, Gdansk, Krakow, Poznan, Warsaw

2020-08-18

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

Bydgoszcz, Koszalin, Krakow, Lodz, Rzeszów, Warsaw, Wroclaw

2020-07-24

Active, closed

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945Pulmonary Arterial Hypertension

DrugMacitentan

Actelion

Phase 3

935

Bialystok, Bydgoszcz, Gdansk, Katowice, Krakow, Szczecin, Warsaw, Wroclaw

2020-06-30

Active, closed

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

NCT04523493Advanced Hepatocellular Carcinoma (HCC)

Shanghai Junshi Bioscience Co., Ltd.

Phase 3

530

Gdansk, Koszalin, Krakow, Mysłowice, Poznan, Skórzewo, Warsaw

2020-06-29

Active, closed

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

996

Poznan, Bydgoszcz, Krakow, Wadowice, Swidnica, Wroclaw, Lublin, Zamość

2020-06-22

Active, closed

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

NCT04437511Alzheimer Disease

DrugDonanemab

Eli Lilly and Company

Phase 3

1,736

Poznan, Bydgoszcz, Krakow, Ścinawa, Wroclaw, Lublin, Warsaw, Warsawawa

2020-06-19

Active, closed

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma

DrugTazemetostat

Epizyme, Inc.

Phase 3

599

Skórzewo, Warsaw, Katowice, Krakow, Torun, Wroclaw

2020-06-11

Active, closed

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596Gastric Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Fluorouracil

AstraZeneca

Phase 2

452

Gdansk, Konin, Koszalin, Krakow, Warsaw

2020-06-03

Active, closed

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

NCT04241185Urinary Bladder Neoplasms

DrugsMitomycin C·Fluorouracil·Adrucil·Keytruda

Merck Sharp & Dohme LLC

Phase 3

520

Krakow, Siedlce, Koszalin

2020-05-19

Active, closed

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT04246047Multiple Myeloma

DrugsBelantamab mafodotin·Bortezomib·Daratumumab·Dexamethasone

GlaxoSmithKline

Phase 3

494

Chorzów, Krakow, Lodz, Lublin, Nowy Sącz, Poznan, Warsaw

2020-05-07

Active, closed

A Study Evaluating the Endovascular Treatment of Subjects With Stenotic or Restenotic Lesions of the Common Femoral Artery With the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery Endarterectomy

NCT04349657Peripheral Arterial Disease

KANDO Research

Not applicable

286

Krakow, Poznan

2020-05-05

Active, closed

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

818

Bydgoszcz, Krakow, Olsztyn, Warsaw

2020-04-16

Active, closed

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04162210Multiple Myeloma

DrugsBelantamab mafodotin·Dexamethasone

GlaxoSmithKline

Phase 3

325

Gdansk, Krakow, Torun

2020-04-02

Active, closed

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

NCT04088396Systemic Juvenile Idiopathic Arthritis

DrugsBaricitinib·Tocilizumab

Eli Lilly and Company

Phase 3

Krakow, Lodz, Warsaw

2020-02-12

Active, closed

A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

NCT04170283B-cell Malignancies

DrugsZanubrutinib·Tislelizumab

BeOne Medicines

Phase 3

955

Bialystok, Brzozów, Bydgoszcz, Chorzów, Gdansk, Gdask, Krakow, Lodz

2020-01-16

Active, closed

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600Hypertension, Pulmonary

DrugSelexipag

Actelion

Phase 3

138

Gdansk, Krakow, Poznan, Warsaw, Wroclaw, Zabrze

2020-01-16

Active, closed

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

NCT04150887Leukemia, Myeloid, Acute

DrugsCusatuzumab·Venclexta·Azacitidine·Venetoclax

OncoVerity, Inc.

Phase 1

Krakow, Lodz, Warsaw

2019-12-23

Recruiting

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

NCT03969329Secondary Hyperparathyroidism

DrugEtelcalcetide

Amgen

Phase 3

Krakow

2019-12-20

Active, closed

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

NCT04130997Relapsing Multiple Sclerosis (RMS)

DrugUblituximab

TG Therapeutics, Inc.

Phase 3

1,100

Katowice, Krakow, Lodz, Olsztyn, Poznan, Warsaw, Zabrze

2019-11-18

Recruiting

Ovarian Hyperstimulation and Fibrin Clot Properties.

NCT04166825Fibrin Blood Clot, Infertility, Female, Endometriosis

Jagiellonian University

Not applicable

300

Krakow

2019-11-18

Active, closed

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors

DrugConcizumab

Novo Nordisk A/S

Phase 3

156

Poznan, Krakow, Warsaw, Lublin, Wroclaw

2019-11-13

Active, closed

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

NCT04025879Carcinoma, Non-Small-Cell Lung

DrugsOpdivo·Pemetrexed·Docetaxel·Nivolumab

Bristol-Myers Squibb

Phase 3

461

Krakow

2019-11-05

Active, closed

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

NCT04083781Haemophilia A With Inhibitors, Haemophilia B With Inhibitors

DrugConcizumab

Novo Nordisk A/S

Phase 3

134

Poznan, Krakow, Warsaw, Lublin, Wroclaw

2019-10-21

Active, closed

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

NCT04050436Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma

DrugsVusolimogene Oderparepvec·Cemiplimab

Replimune, Inc.

Phase 2

231

Gdansk, Krakow, Warsaw, Wroclaw

2019-10-08

Active, closed

SyncAV Post-Market Trial

NCT04100148Congestive Heart Failure

Abbott Medical Devices

Not applicable

1,686

Krakow, Poznan

2019-10-03

Active, closed

A Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta

NCT04253015Neuroblastoma

RECORDATI GROUP

Observational

125

Krakow

2019-09-30

Active, closed

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

NCT04006210Parkinson's Disease

NeuroDerm Ltd.

Phase 3

381

Krakow, Lodz, Siemianowice Śląskie, Warsaw

2019-09-30

Active, closed

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445Ulcerative Colitis

DrugGuselkumab

Janssen Research & Development, LLC

Phase 2/3

1,064

Bialystok, Bydgoszcz, Krakow, Lublin, Oświęcim, Rzeszów, Sopot, Szczecin

2019-09-26

By invitation

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension

United Therapeutics

Phase 3

1,000

Bialystok, Krakow, Otwock, Poznan, Wroclaw

2019-09-23

Active, closed

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

NCT04083339Diabetic Cardiomyopathies

Applied Therapeutics, Inc.

Phase 3

675

Wroclaw, Bialystok, Krakow, Lodz, Poznan, Radom, Rzeszów

2019-09-20

Recruiting

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant

DrugsTulmimetostat·Enzalutamide

Novartis Pharmaceuticals

Phase 1/2

300

Gdansk, Krakow, Lodz, Poznan, Warsaw

2019-09-18

Active, closed

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

NCT03992404Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury

DrugXeomin

Merz Pharmaceuticals GmbH

Phase 3

603

Katowice, Krakow, Lodz, Lublin, Warsaw, Wroclaw

2019-09-16

Active, closed

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma

DrugsVenclexta·Venetoclax

AbbVie

Phase 3

165

Krakow, Warsaw, Chorzów

2019-09-06

Recruiting

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

NCT04043494Lymphoblastic Lymphoma, Childhood

DrugsVindesine·Thioguanine·PEG-Asparaginase·Ifosfamide

University Hospital Muenster

Phase 3

683

Bialystok, Bydgoszcz, Chorzów, Gdansk, Kielce, Krakow, Lodz, Lublin

2019-08-23

Active, closed

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

DrugsBendamustine·Zanubrutinib·Rituximab

BeOne Medicines

Phase 3

510

Bydgoszcz, Chorzów, Gdansk, Gdask, Gdynia, Krakow, Legnica, Lodz

2019-08-20

Recruiting

Pan Tumor Rollover Study

NCT03899155Cancer

DrugsRucaparib·Sunitinib·Trametinib·Relatlimab

Bristol-Myers Squibb

Phase 2

1,500

Bydgoszcz, Olsztyn, Biała Podlaska, Gdansk, Krakow, Lodz, Lublin, Poznan

2019-08-09

Active, closed

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

NCT03767244Prostatic Neoplasms

DrugApalutamide

Janssen Research & Development, LLC

Phase 3

2,517

Bydgoszcz, Koszalin, Krakow, Warsaw, Wroclaw

2019-06-11

Active, closed

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004Cutaneous Squamous Cell Carcinoma

DrugCemiplimab

Regeneron Pharmaceuticals

Phase 3

415

Gliwice, Krakow, Poznan, Warsaw

2019-06-04

Active, closed

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561Diabetes Mellitus, Type 2

DrugSemaglutide

Novo Nordisk A/S

Phase 3

1,500

Bialystok, Bydgoszcz, Chorzów, Gdansk, Katowice, Krakow, Lodz, Poznan

2019-05-08

Recruiting

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

NCT03773965Juvenile Idiopathic Arthritis

DrugBaricitinib

Eli Lilly and Company

Phase 3

190

Krakow, Lodz, Warsaw

2019-04-05

Recruiting

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia

NCT03813407Hyperkalaemia

DrugPumitamig

AstraZeneca

Phase 3

140

Bialystok, Krakow, Lodz, Warsaw

2019-04-02

Active, closed

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

NCT03675308Psoriatic Arthritis

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

964

Bydgoszcz, Torun, Krakow, Grodzisk Mazowiecki, Warsaw, Bialystok, Elblag, Olsztyn

2019-03-25

Active, closed

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

NCT03591510FLT3-mutated Acute Myeloid Leukemia

DrugsMidostaurin·Mitoxantrone·Idarubicin·Daunorubicin

Novartis Pharmaceuticals

Phase 2

Krakow

2019-03-13

Active, closed

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261Chronic Lymphocytic Leukemia

DrugsAcalabrutinib·Venclexta·Obinutuzumab·Venetoclax

Acerta Pharma BV

Phase 3

984

Brzozów, Bydgoszcz, Gdynia, Krakow, Lodz, Lublin, Wroclaw

2019-02-25

Active, closed

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935Advanced Solid Tumors Cancer

DrugsLivmoniplimab·Budigalimab

AbbVie

Phase 1

364

Krakow, Warsaw, Lodz

2019-02-21

Active, closed

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032High-risk Non-muscle Invasive Bladder Cancer

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,397

Poznan, Torun, Krakow, Tarnów, Wroclaw, Siedlce, Warsaw, Przemyśl

2018-12-24

Active, closed

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

NCT03742102Triple Negative Breast Neoplasms

DrugsOleclumab·Capivasertib·Dato-DXd·Trastuzumab deruxtecan

AstraZeneca

Phase 1/2

243

Gdansk, Krakow, Lublin, Opole, Rzeszów, Warsaw

2018-12-21

Active, closed

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

NCT03737214Fabry Disease

Idorsia Pharmaceuticals Ltd.

Phase 3

107

Krakow, Warsaw

2018-12-18

Active, closed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918Head and Neck Neoplasms

DrugsKeytruda·Cisplatin·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

714

Krakow, Warsaw, Gdynia, Gliwice, Lodz

2018-12-17

Active, closed

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

NCT03710603Multiple Myeloma

DrugsVelcade·Bortezomib·Daratumumab·Lenalidomide

Stichting European Myeloma Network

Phase 3

709

Krakow

2018-12-14

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

DrugRibociclib

Novartis Pharmaceuticals

Phase 3

5,101

Warsaw, Bialystok, Gdynia, Gliwice, Grudziądz, Krakow, Lodz, Lublin

2018-12-07

Active, closed

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

NCT03562637Triple Negative Breast Cancer

OBI Pharma, Inc

Phase 3

575

Gdansk, Krakow, Lodz, Warsaw

2018-12-05

Active, closed

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NCT03732677Muscle Invasive Bladder Cancer

DrugsDurvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,063

Bialystok, Gdansk, Grudziądz, Koszalin, Krakow, Olsztyn, Ostrołęka, Poznan

2018-11-16

Active, closed

A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT03596645Colitis, Ulcerative

DrugsGolimumab·Infliximab

Janssen Research & Development, LLC

Phase 3

Bydgoszcz, Gdansk, Krakow, Olsztyn, Rzeszów, Warsaw

2018-10-29

Active, closed

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

DrugsPonatinib·Imatinib·Cytarabine·Vincristine

Takeda

Phase 3

245

Krakow, Wroclaw, Gdansk, Olsztyn

2018-10-04

Recruiting

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

NCT03838926Relapsed or Refractory Hematologic Malignancies

DrugTrichostatin A

Vanda Pharmaceuticals

Phase 1

Biała Podlaska, Katowice, Krakow, Opole, Skorzewo, Warsaw, Wroclaw

2018-09-27

Active, closed

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,246

Bialystok, Gdansk, Grudziądz, Koszalin, Krakow, Olsztyn, Poznan, Radom

2018-09-27

Active, closed

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836Melanoma

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

976

Poznan, Bydgoszcz, Krakow, Warsaw, Rzeszów, Gdansk, Bielsko-Biala, Katowice

2018-09-12

Active, closed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135Ulcerative Colitis (UC)

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,242

Bydgoszcz, Torun, Krakow, Wroclaw, Warsaw, Sopot, Katowice, Tychy

2018-08-28

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Konin, Poznan, Bydgoszcz, Krakow, Warsaw, Opole, Bialystok, Gdansk

2018-08-21

Active, closed

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

NCT03456076Carcinoma, Non-Small-Cell Lung

DrugsAlectinib·Vinorelbine·Pemetrexed·Gemcitabine

Hoffmann-La Roche

Phase 3

257

Gda?sk, Krakow, Olsztyn, Poznan

2018-08-16

Recruiting

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

NCT03619850Chronic Kidney Disease; Iron Deficiency Anemia

DrugsIron sucrose·Ferumoxytol

AMAG Pharmaceuticals, Inc.

Phase 3

129

Bialystok, Krakow, Lodz

2018-08-13

Active, closed

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

NCT03519945Ulcerative Colitis

DrugMirikizumab

Eli Lilly and Company

Phase 3

1,058

Będzin, Bydgoszcz, Elblag, Katowice, Krakow, Lublin, Nowy Targ, Olsztyn

2018-07-18

Recruiting

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

NCT03592472Renal Cell Carcinoma

DrugsAbexinostat·Pazopanib

Xynomic Pharmaceuticals, Inc.

Phase 3

413

Brzozów, Gdynia, Krakow, Poznan

2018-07-17

Active, closed

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL

DrugEpcoritamab

Genmab

Phase 1/2

666

Bydgoszcz, Gdansk, Krakow, Słupsk, Warsaw, Wroclaw

2018-06-26

Active, closed

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

NCT03523858Progressive Multiple Sclerosis (PMS)

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

927

Bialystok, Krakow, Lodz, Późna, Rzeszów, Warsaw, Zabrze

2018-05-28

Recruiting

A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

NCT03571568Indolent B-Cell Non-Hodgkin Lymphoma

DrugsRuxience·Acalabrutinib·Rituximab

BioInvent International AB

Phase 1/2

140

Grudziądz, Krakow

2018-05-16

Active, closed

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

NCT03604198Cushing Syndrome

DrugRelacorilant

Corcept Therapeutics

Phase 2

125

Krakow, Lublin

2018-05-07

Active, closed

Extended Access of Momelotinib in Adults With Myelofibrosis

NCT03441113Primary Myelofibrosis

GlaxoSmithKline

Phase 2

237

Brzozów, Chorzów, Gdansk, Krakow, Lublin, Opole, Poznan

2018-05-03

Recruiting

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)

DrugsMevrometostat·Xtandi·Itraconazole·Enzalutamide

Pfizer

Phase 1

453

Bydgoszcz, Koszalin, Krakow, Rzeszów, Warsaw

2018-04-17

Active, closed

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03466411Crohn's Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab

Janssen Research & Development, LLC

Phase 2/3

1,409

Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Jelenia Góra, Katowice, Krakow

2018-04-13

Active, closed

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

747

Krakow, Wroclaw, Warsaw

2018-03-21

Active, closed

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847Metastatic Triple Negative Breast Cancer

DrugCeralasertib

AstraZeneca

Phase 2

273

Dąbrowa Górnicza, Gdansk, Gdynia, Grzepnica, Krakow, Lodz, Olsztyn, Poznan

2018-03-07

Recruiting

DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL

NCT03959748Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension

Polish Cardiology Association

Observational

3,000

Krakow

2018-03-01

Active, closed

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT03328273Chronic Lymphocytic Leukemia

DrugsCeralasertib·Acalabrutinib

Acerta Pharma BV

Phase 1

Krakow, Lodz

2018-01-31

Recruiting

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

NCT03328078Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma

DrugsEmavusertib·Ibrutinib

Curis, Inc.

Phase 1/2

152

Gdansk, Krakow, Warsaw

2017-12-28

Active, closed

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsBendamustine·Venclexta·Zanubrutinib·Venetoclax

BeiGene

Phase 3

590

Brzozów, Chorzów, Gdansk, Gdynia, Gliwice, Krakow, Legnica, Lodz

2017-10-31

Active, closed

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

NCT03212404Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced

Checkpoint Therapeutics, Inc.

Phase 1

272

Krakow, Lodz, Lublin, Poznan, Warsaw

2017-09-20

Active, closed

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

DrugPacritinib

Swedish Orphan Biovitrum

Phase 3

407

Bialystok, Gdansk, Katowice, Krakow, Lodz, Lublin, Nowy Sącz, Rzeszów

2017-06-26

Active, closed

Xeltis Bioabsorbable Pulmonary Valved Conduit Pivotal Study

NCT03022708Heart Defect, Congenital

Xeltis

Not applicable

Krakow

2017-05-08

Active, closed

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

NCT02972840Lymphoma, Mantle Cell

DrugsAcalabrutinib·Bendamustine·Rituximab

Acerta Pharma BV

Phase 3

635

Chorzów, Krakow, Lodz, Lublin, Olsztyn, Warsaw, Woj. Podkarpackie, Wroclaw

2017-04-05

Active, closed

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

NCT02970318Chronic Lymphocytic Leukemia

DrugsIdelalisib·Acalabrutinib·Bendamustine·Rituximab

Acerta Pharma BV

Phase 3

310

Bialystok, Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Woj. Podkarpackie

2017-02-02

Active, closed

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

NCT02993523Acute Myeloid Leukemia (AML)

DrugsAzacitidine·Venetoclax

AbbVie

Phase 3

443

Krakow, Wroclaw, Chorzów

2017-02-02

Active, closed

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

NCT02955940Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer

DrugsRegorafenib·Xeloda·Ruxolitinib·Capecitabine

Incyte Corporation

Phase 2

Krakow, Lublin, Warsaw

2016-11-30

By invitation

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

NCT02796937Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

Grifols Therapeutics LLC

Phase 3

290

Krakow, Warsaw

2016-07

Active, closed

A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

NCT02726386Parkinson's Disease

NeuroDerm Ltd.

Phase 2

214

Krakow, Lublin

2016-05-04

Active, closed

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

NCT02717624Mantle Cell Lymphoma (MCL)

DrugAcalabrutinib

Acerta Pharma BV

Phase 1

Krakow, Lodz, Olsztyn, Warsaw

2016-04-20

Active, closed

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159Rheumatoid Arthritis

DrugsHumira·Adalimumab·Upadacitinib

AbbVie

Phase 3

1,629

Torun, Cracow, Krakow, Wroclaw, Lublin, Grodzisk Mazowiecki, Warsaw, Bialystok

2015-12-01

Active, closed

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

NCT02489318Prostate Cancer

DrugApalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,052

Bialystok, Bydgoszcz, Krakow, Kutno, Lodz, Lublin, Siedlce, Sochaczew

2015-11-27

Active, closed

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

NCT02542293Non Small Cell Lung Carcinoma NSCLC

DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine

AstraZeneca

Phase 3

953

Bydgoszcz, Kielce, Krakow, Lodz, Mrozy, Olsztyn, Poznan, Warsaw

2015-11-03

Active, closed

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma

DrugOsimertinib

AstraZeneca

Phase 3

682

Krakow, Lodz, Otwock, Poznan, Racibórz, Warsaw, Wieliszew

2015-10-21

Active, closed

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

NCT02612454Atopic Dermatitis

DrugDupilumab

Regeneron Pharmaceuticals

Phase 3

880

Ostrowiec Świętokrzyski, Wroclaw, Krakow, Katowice, Bialystok, Bydgoszcz, Chorzów, Gdansk

2015-10-15

Active, closed

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

NCT02477696Chronic Lymphocytic Leukemia

DrugsIbrutinib·Acalabrutinib

Acerta Pharma BV

Phase 3

533

Bydgoszcz, Gdansk, Gdynia, Krakow, Lodz, Olsztyn, Opole, Słupsk

2015-07-28

Active, closed

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

NCT02475681Chronic Lymphocytic Leukemia

DrugsChlorambucil·Acalabrutinib·Obinutuzumab

Acerta Pharma BV

Phase 3

535

Bydgoszcz, Gdansk, Gdynia, Krakow, Lodz, Lublin, Olsztyn, Opole

2015-06-26

Recruiting

@neurIST : Intregrated Biomedical Informatics for the Management of Cerebral Aneurysms

NCT05526352Intracranial Aneurysm

University Hospital, Geneva

Observational

20,000

Krakow

2015-06-01

Active, closed

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

NCT02213926Mantle Cell Lymphoma (MCL)

DrugAcalabrutinib

Acerta Pharma BV

Phase 2

124

Krakow, Lodz, Olsztyn

2015-03-02

Active, closed

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02227251Diffuse Large B-cell Lymphoma

DrugSelinexor

Karyopharm Therapeutics Inc

Phase 2

244

Wroclaw, Gdynia, Krakow, Legnica, Lodz, Lublin, Olsztyn, Warsaw

2014-11

Active, closed

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

NCT02143466Advanced Non Small Cell Lung Cancer

DrugsSavolitinib·Selumetinib·Osimertinib·Durvalumab

AstraZeneca

Phase 1

344

Gdansk, Krakow, Olsztyn, Poznan, Warsaw

2014-08-05

Active, closed

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

DrugsPegylated G-CSF·Pegfilgrastim·Selumetinib·Docetaxel

AstraZeneca

Phase 3

510

Brzozów, Bydgoszcz, Gdansk, Grudziądz, Krakow, Lubin, Olsztyn, Opole

2013-09-25

Active, closed

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

DrugIbrutinib

Janssen Research & Development, LLC

Phase 3

539

Brzozów, Chorzów, Gdansk, Klinika Nowotworow Ukladu Chlonnego, Krakow, Opole, Słupsk, Wroclaw

2013-09-09

Recruiting

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

NCT01949129Acute Lymphoblastic Leukaemia

DrugsGrafalon·Treosulfan·Thiotepa·Busulfan

St. Anna Kinderkrebsforschung

Phase 2/3

1,800

Bydgoszcz, Krakow, Lublin, Poznan, Wroclaw

2013-04

Recruiting

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

NCT01574053Huntington's Disease

CHDI Foundation, Inc.

Observational

35,000

Gdansk, Katowice, Krakow, Poznan, Warsaw

2012-07

Recruiting

International (Pediatric) Peritoneal Biobank

NCT01893710Kidney Failure, Chronic, Peritoneal Dialysis Complication, Transplantation, Healthy

Heidelberg University

Observational

500

Krakow

2011-02-01

Recruiting

Effects of Oncological Treatment During Pregnancy on Mother and Child

NCT00330447Cancer, Pregnancy

University Hospital, Gasthuisberg

Observational

5,000

Krakow, Poznan

2005-08

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-poland/city/krakow?page=2

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 882 of those studies with a site in Krakow.

How many clinical trials are recruiting in Krakow?

450 of the 882 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 15 have not yet opened recruitment, 392 are active but closed to new participants, and 25 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.